Mirum Plans 2027 Hepatitis D Filing After Phase 3 Win as U.S. Patients Rely on One Approved Drug

Mirum’s hepatitis D antibody met its Phase 3 goal, and a 2027 FDA filing is planned. Hepcludex remains the only approved U.S. treatment.

Have A Referral?